(Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 ...

BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...

German biotech firm's revenues down 27% compared to 2023, according to company's financial report - Anadolu Ajansı ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

BofA lowered the firm’s price target on BioNTech (BNTX) to $143 from $147 and keeps a Buy rating on the shares after the company reported ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

Half of the patients who received an experimental vaccine for pancreas cancer being developed by Roche and BioNTech following ...